DE69718469T2 - Verbindungen mit wachtumshormon freisetzenden eigenschaften - Google Patents
Verbindungen mit wachtumshormon freisetzenden eigenschaftenInfo
- Publication number
- DE69718469T2 DE69718469T2 DE69718469T DE69718469T DE69718469T2 DE 69718469 T2 DE69718469 T2 DE 69718469T2 DE 69718469 T DE69718469 T DE 69718469T DE 69718469 T DE69718469 T DE 69718469T DE 69718469 T2 DE69718469 T2 DE 69718469T2
- Authority
- DE
- Germany
- Prior art keywords
- growth hormone
- connections
- hormone releasing
- releasing properties
- properties
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK48996 | 1996-04-24 | ||
| DK134496 | 1996-11-26 | ||
| PCT/DK1997/000186 WO1997040023A1 (en) | 1996-04-24 | 1997-04-24 | Compounds with growth hormone releasing properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69718469D1 DE69718469D1 (de) | 2003-02-20 |
| DE69718469T2 true DE69718469T2 (de) | 2003-10-30 |
Family
ID=26064097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69718469T Expired - Fee Related DE69718469T2 (de) | 1996-04-24 | 1997-04-24 | Verbindungen mit wachtumshormon freisetzenden eigenschaften |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0907643B1 (de) |
| JP (1) | JP4359859B2 (de) |
| KR (1) | KR20000010626A (de) |
| CN (1) | CN1127488C (de) |
| AT (1) | ATE231131T1 (de) |
| AU (1) | AU722421B2 (de) |
| BR (1) | BR9708854A (de) |
| CA (1) | CA2252761A1 (de) |
| CZ (1) | CZ291982B6 (de) |
| DE (1) | DE69718469T2 (de) |
| HU (1) | HUP9902668A3 (de) |
| IL (1) | IL126235A (de) |
| NO (1) | NO312242B1 (de) |
| PL (1) | PL329413A1 (de) |
| WO (1) | WO1997040023A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0986551B1 (de) * | 1997-05-30 | 2006-08-02 | Takeda Pharmaceutical Company Limited | Sulfonamidderivate, ihre herstellung und verwendung |
| EP1054005A4 (de) | 1998-02-05 | 2003-02-05 | Takeda Chemical Industries Ltd | Sulfonamidderivate, verfahren zu ihrer herstellung und ihre verwendung |
| US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| EP1930021A3 (de) | 1999-02-18 | 2008-06-18 | Kaken Pharmaceutical Co., Ltd. | Neue Amidderivate als Wachstumshormonssekretagoge |
| EP1159964B1 (de) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
| AR030817A1 (es) | 2000-10-02 | 2003-09-03 | Novartis Ag | Derivados de diazacicloalcanodiona |
| US6710061B2 (en) | 2001-03-09 | 2004-03-23 | Ortho-Mcneil Pharamceutical, Inc. | Aminopyrrolidine sulfonamides as serine protease inhibitors |
| JP2004520438A (ja) | 2001-03-09 | 2004-07-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | セリンプロテアーゼインヒビターとしてのアミノピロリジンスルホンアミド |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| MX2009008574A (es) | 2007-02-09 | 2009-12-09 | Tranzyme Pharma Inc | Moduladores del receptor de grelina macrociclicos y metodos para usar el mismo. |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| CN108129404B (zh) * | 2018-01-30 | 2020-05-01 | 凯瑞斯德生化(苏州)有限公司 | 手性哌嗪酮衍生物的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98910A0 (en) * | 1990-07-24 | 1992-07-15 | Polygen Holding Corp | Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them |
| US5663146A (en) * | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
| US5767085A (en) * | 1993-12-23 | 1998-06-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
-
1997
- 1997-04-24 AU AU26345/97A patent/AU722421B2/en not_active Ceased
- 1997-04-24 IL IL12623597A patent/IL126235A/xx not_active IP Right Cessation
- 1997-04-24 EP EP97918075A patent/EP0907643B1/de not_active Expired - Lifetime
- 1997-04-24 KR KR1019980708527A patent/KR20000010626A/ko not_active Application Discontinuation
- 1997-04-24 BR BR9708854A patent/BR9708854A/pt not_active IP Right Cessation
- 1997-04-24 PL PL97329413A patent/PL329413A1/xx unknown
- 1997-04-24 CA CA002252761A patent/CA2252761A1/en not_active Abandoned
- 1997-04-24 JP JP53762397A patent/JP4359859B2/ja not_active Expired - Lifetime
- 1997-04-24 DE DE69718469T patent/DE69718469T2/de not_active Expired - Fee Related
- 1997-04-24 CZ CZ19983390A patent/CZ291982B6/cs not_active IP Right Cessation
- 1997-04-24 CN CN97194057A patent/CN1127488C/zh not_active Expired - Fee Related
- 1997-04-24 WO PCT/DK1997/000186 patent/WO1997040023A1/en not_active Application Discontinuation
- 1997-04-24 HU HU9902668A patent/HUP9902668A3/hu unknown
- 1997-04-24 AT AT97918075T patent/ATE231131T1/de not_active IP Right Cessation
-
1998
- 1998-10-23 NO NO19984950A patent/NO312242B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2252761A1 (en) | 1997-10-30 |
| HUP9902668A2 (hu) | 2000-04-28 |
| JP2000508666A (ja) | 2000-07-11 |
| AU722421B2 (en) | 2000-08-03 |
| NO984950L (no) | 1998-12-21 |
| HU9902668D0 (en) | 1999-09-28 |
| PL329413A1 (en) | 1999-03-29 |
| ATE231131T1 (de) | 2003-02-15 |
| CZ291982B6 (cs) | 2003-06-18 |
| AU2634597A (en) | 1997-11-12 |
| WO1997040023A1 (en) | 1997-10-30 |
| EP0907643B1 (de) | 2003-01-15 |
| IL126235A (en) | 2003-02-12 |
| NO984950D0 (no) | 1998-10-23 |
| JP4359859B2 (ja) | 2009-11-11 |
| IL126235A0 (en) | 1999-05-09 |
| CN1127488C (zh) | 2003-11-12 |
| DE69718469D1 (de) | 2003-02-20 |
| CN1216537A (zh) | 1999-05-12 |
| EP0907643A1 (de) | 1999-04-14 |
| KR20000010626A (ko) | 2000-02-25 |
| BR9708854A (pt) | 1999-08-03 |
| NO312242B1 (no) | 2002-04-15 |
| HUP9902668A3 (en) | 2000-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69718469D1 (de) | Verbindungen mit wachtumshormon freisetzenden eigenschaften | |
| ATE197158T1 (de) | Verbindungen mit wachstumshormonfreisetzenden eigenschaften | |
| EP0528858A4 (en) | Inhibitors of dipeptidyl-aminopeptidase type iv | |
| BG105783A (en) | Triazole compounds with dopamine-d3-receptor affinity | |
| CY2431B1 (en) | Novel phenanthridines substituted in the 6 position. | |
| DE69941255D1 (de) | Verbindungen mit wachstumshormon freisetzenden eigenschaften | |
| DE69130497T2 (de) | Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis | |
| MX9701187A (es) | Nuevas lactamas naftofusionadas n-substituidas. | |
| DE69418744D1 (de) | Verwendung von Pregnanderivaten zur Behandlung von Tumoren | |
| DE69943239D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| ES2135722T3 (es) | 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina. | |
| GB9302046D0 (en) | Antiumoral compound-v | |
| DE69921611D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
| DE69919195D1 (de) | Verbindungen mit wachstumshormon-freisetzender eigenschaft | |
| ATE128867T1 (de) | Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SAPPHIRE THERAPEUTICS, INC., BRIDGEWATER, N.J., US |
|
| 8339 | Ceased/non-payment of the annual fee |